LINEZOLID RESISTANCE IN STAPHYLOCOCCUS AUREUS: AN EMERGING PROBLEM

Dr Kiranjeet Kaur, Dr Mandeep Kaur, Dr Amarjit Kaur Gill

Abstract


BACKGROUND: Linezolid is a precious drug used to treat infections by resistant Gram positive cocci. Resistance to linezolid is either by
G2576T mutation or plasmid mediated cfr gene.
AIM: This study aimed to find out the prevalence of linezolid resistance among S. aureus. Methods & Materials: The study was conducted in a
tertiary care hospital from July 2016 to June 2017. All clinical isolates of S. aureus were subjected to antimicrobial susceptibility testing by Kirby-
Bauer disc diffusion method. The confirmed LRSA were included in the study. Clinical details of the patients were analyzed.
RESULTS: Out of 162 S. aureus isolates, eight showed resistance for linezolid. Most LRSA strains were isolated from soft tissue infections.
Vancomycin showed susceptibility in 87.5% LRSA strains while teicoplanin and tigecycline were 100% susceptible.
CONCLUSION: Linezolid resistance in S. aureus poses a significant challenge in the treatment of infectious diseases. The continued
antimicrobial surveillance and stopping injudicious antibiotics use is necessity.


Keywords


Bacterial Infection, Drug Resistance, Linezolid Resistance, Antimicrobial Agents

Full Text:

PDF

References


MacKenzie FM, Bruce J, Struelens MJ, Goossens H, Mollison J, Gould IM, et al. Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals, Clin Microbiol Infect. 2007;13(3):269-76.

National Nosocomial Infection Surveillance (NNIS) system report, data summary from January 1992-june 2001, issued August 2001. Am J Infect Control 2001;29:404-21.

Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358(9297):1975-82.

Aoki H, Ke L, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, et al. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother. 2002;46(4):1080–5.

Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1996;40(3):799–801.

Ross JE, Farrell DJ, Mendes RE , Sader HS, Jones RN. Eight-year (2002–2009) summary of the linezolid (Zyvox(R) Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. J Chemother. 2011;23(2):71-6.

Campanile F, Mongelli G, Bongiorno D, Adembri C, Ballardini M, Falcone M, et al. Worrisome trends of new multiple mechanisms of linezolid resistant in staphylococcal clones diffused in Italy. J Clin Microbiol. 2013;51):1256-9.

Clinical and Laboratory standard institute (CSLI). Performance standards for antimicrobial susceptibility testing. 26th ed. CLSI supplement. M100S.

Bing G, Thedoros K, Sotios T. The emerging problem of linezolid –resistant Staphylococcus. J Antimicrob Chemother. 2012;69(1):1-37.

Long KS, Vester B. Resistance to linezolid caused by modification at its binding site on the ribosome. Antimicrob Agents Chemother. 2012;56(2):603-12.

Kehrenberg C, Aarestrup FM, Schwarz S. IS 21-558 insertion sequences are involved in mobility of multiresistance gene cfr. Antimicrob Agents Chemother. 2007;51(2):483-7.

Diekema D, Pfaller M, Schmitz F,Smayevsky J, Bell J, Jones RN et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis. 2001;32(Suppl2):S114–32.

Mark H. Wilcox. Efficacy of linezolid versus comparator therapies in Gram-positive infections. Journal of Antimicrobial Chemotherapy. 2003;51(S2):27–35.

Sánchez García M, De la Torre MA, Morales G, Peláez B, Tolón MJ, Domingo S, et al. Clinical outbreak of Linezolid-resistant Staphylococcus aureus in an Intensive Care Unit. JAMA. 2010;303(22):2260-4.

Stefani S, Bongiorno D, Mongelli G, Campanile F. Linezolid resistance in staphylococci. Pharmaceuticals.2010;3(7):1988-2006.

Tsiodras S, Gold HS, SakoulasG, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358(9277):207-8.

Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksoudszian A, Hujer AM, et al. Emergence of Linezolid –Resistance Staphylococcus aureus after Prolong Treatment of Cystic Fibrosis Patients in Cleveland, Ohio.Antimicrob Agent Chemother. 2011;55(4):1684-92.

Ikeda –Dantsuji Y, Hanakin H, Sakai F, Tomono K, Takesue Y, Honda j, et al. Linezolid- resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospital in japan. J infect chemother. 2011;17(1):45-51.

Norma V, Juan Carlos V, Gerado EV. Resistance to linezolid of methicillin-resistant Staphylococcus aureus and Enterococcus with high level resistance to aminoglycosides at a third level pediatric hospital. Bol Med Hosp Infant Mex. 2010;67:17-24.19.

Harcharan Singh, Meena Atray, Pankaj Kumar Modi. Antibiotic susceptibility pattern of methicillin resistant Staphylococcus aureus in tertiary care center at Southern Rajasthan. IJPSR. 2014;5(2):607- 11

Rajaduraipandi K, Mani KR, Panneerselvam K, Mani M, Bhaskar M, Manikandam P. Prevalence and antimicrobial susceptibility pattern of Methicillin resistant Staphylococcus aureus: A multicenter study. Indian J Med Microbiol. 2006;24(1):34-8.

Lyra PR, Anuradha K, Shilpa A and Venkateshha D. Linezolid resistance in isolates of methicillin resistant Staphylococci from blood cultures. Int J Pharma Bio Sci. 2013;4(4):1085-90.

Wilson P, Andrews JA, charlesworth R. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob chemother. 2003;51(1):186-8.

Mendes RE, Deshpande L, Rodriguez- Noriego E et al. First report of staphylococcal clinical isolates in Mexico with linezilide resistance caused by cfr: evidence of in vivo cfr mobilization. J Clin Microbial. 2010:48(8):3041-3.


Refbacks

  • There are currently no refbacks.